Pleiotropic cancer manifestations of germline CDH1 mutations: Risks and management.
CDH1
hereditary cancer
penetrance risk
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
27
02
2022
received:
22
02
2022
accepted:
27
02
2022
pubmed:
13
3
2022
medline:
17
5
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
Germline CDH1 defects are related with the development of multiple cancers due its pleiotropic nature. These several conditions are associated with various risks of penetrance and with different clinical management strategies. In this clinical review, we described the penetrance risks of gastric, breast, prostate, and colorectal cancers, in CDH1 carriers, within as well as outside the familial setting, and the best approaches to manage each risk, using either prophylactic surgery or surveillance.
Identifiants
pubmed: 35277969
doi: 10.1002/jso.26847
pmc: PMC9313879
doi:
Substances chimiques
Antigens, CD
0
CDH1 protein, human
0
Cadherins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326-1331Informations de copyright
© 2022 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC.
Références
N Z Med J. 1964 May;63:287-96
pubmed: 14158754
J Med Genet. 2015 Jun;52(6):361-74
pubmed: 25979631
J Surg Oncol. 2022 Jun;125(8):1326-1331
pubmed: 35277969
Ann Oncol. 2021 Oct;32(10):1216-1235
pubmed: 34242744
J Med Genet. 2022 Jan 25;:
pubmed: 35078942
Science. 1991 Mar 22;251(5000):1451-5
pubmed: 2006419
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809393
JAMA Oncol. 2015 Apr;1(1):23-32
pubmed: 26182300
JAMA Oncol. 2019 Sep 01;5(9):1325-1331
pubmed: 31246251
J Med Genet. 2019 Apr;56(4):199-208
pubmed: 30661051
Lancet Oncol. 2020 Aug;21(8):e386-e397
pubmed: 32758476
J Med Genet. 2019 Dec;56(12):838-843
pubmed: 31296550
World J Gastroenterol. 2006 Jan 14;12(2):199-203
pubmed: 16482618
Hum Mol Genet. 2007 Jul 1;16(13):1639-47
pubmed: 17510211
Cancers (Basel). 2021 May 12;13(10):
pubmed: 34066044
Curr Opin Cell Biol. 1993 Oct;5(5):806-11
pubmed: 8240824
Nature. 1998 Mar 26;392(6674):402-5
pubmed: 9537325
J Biol Chem. 1991 Oct 15;266(29):19672-80
pubmed: 1918074
J Med Genet. 1999 Dec;36(12):873-80
pubmed: 10593993
Expert Rev Mol Diagn. 2003 Mar;3(2):201-15
pubmed: 12647996
J Clin Oncol. 2013 Mar 1;31(7):868-75
pubmed: 23341533
EMBO J. 1995 Dec 15;14(24):6107-15
pubmed: 8557030
Trends Biochem Sci. 1999 Feb;24(2):73-6
pubmed: 10098402
JAMA Surg. 2022 Jan 1;157(1):18-22
pubmed: 34643667
Oncotarget. 2017 Mar 7;8(10):16445-16455
pubmed: 28147315
J Med Genet. 2022 Apr;59(4):313-317
pubmed: 34952833
Clin Cancer Res. 2001 Nov;7(11):3465-71
pubmed: 11705864
Trends Cell Biol. 2004 Aug;14(8):427-34
pubmed: 15308209
J Clin Oncol. 2021 Dec 10;39(35):3918-3926
pubmed: 34672684
Eur J Cancer Prev. 2022 May 1;31(3):274-278
pubmed: 33990097
J Med Genet. 2018 Jul;55(7):431-441
pubmed: 29929997
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560361
J Cell Mol Med. 2020 Jun;24(11):5930-5936
pubmed: 32301282
Curr Treat Options Gastroenterol. 2020 Dec;18(4):604-615
pubmed: 33776403
Hum Mol Genet. 2003 Nov 15;12(22):3007-16
pubmed: 14500541
Cancer Metastasis Rev. 2014 Dec;33(4):1081-94
pubmed: 25332147